Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Reply to Ghosh et al ¹ . Comments on Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder.

Autor: Ahmad A; Jina Pharmaceuticals Inc., Libertyville, Illinois, USA., Sheikh S; Jina Pharmaceuticals Inc., Libertyville, Illinois, USA., Khan MA; Intas Pharmaceuticals Ltd., Ahmedabad, India., Chaturvedi A; Intas Pharmaceuticals Ltd., Ahmedabad, India., Patel P; Intas Pharmaceuticals Ltd., Ahmedabad, India., Patel R; Lambda Therapeutic Research Ltd., Ahmedabad, India., Buch BC; Shri Hatkesh Healthcare Foundation, Junagadh, India., Anand RS; Kanoria Hospital and Research Centre, Bhat, Gandhinagar, India., Shah TC; Divyam Hospital, Surat, India., Vora VN; Ratandeep Multispecialty Hospital, Ahmedabad, India., Ramasubramanian V; Ahana Hospitals, Madurai, India., Rao S; JSS Medical College Hospital, Mysore, India., Kumar N; Mysore Medical College and Research Institute, K.R. Hospital, Mysore, India., Prasad BSV; Sujata Birla Hospital and Medical Research Center, Nasik, India., Sathianathan R; Sri Ramachandra Medical College and Research Institute, Chennai, India., Verma KK; S.P. Medical College and A.G. Hospitals, Bikaner, India., Jhanwar VG; Deva Institute of Healthcare and Research, Varanasi, India., Kumar N; All India Institute of Medical Sciences, New Delhi, India., Shah S; Gujarat Medical Education & Research Society Medical College, Gotri, India., Dalal PK; King George's Medical University, G.M. Associated Hospitals, Lucknow, India., Sindhu B; Civil Hospital, Gurugram, India., Talukdar P; Nil Ratan Sircar Medical College and Hospital, Kolkata, India., Ahmad I; Jina Pharmaceuticals Inc., Libertyville, Illinois, USA.

Publikováno v: Bipolar disorders [Bipolar Disord] 2022 Feb; Vol. 24 (1), pp. 91-92. Date of Electronic Publication: 2021 Nov 23.